As soon as Celgene (NASDAQ:CELG) – the prominent biopharmaceutical company – reported earnings results that were unexpectedly well, and updates of its study of Crohn’s disease which went encouraging enough, it shares increased by 13% in the previous month as reported by S&P Capital IQ.

Vey recently Celgene (NASDAQ:CELG) reported its third-quarter earnings reports and growth in earnings, little cost-cutting and refraining from taking buyback measures were major highpoints of the report.

With the start of the new quarter, Celgene (NASDAQ:CELG) is set up to achieve its set objectives. Celgene (NASDAQ: CELG) expects its sales to rise up to $1.98 billion which is an 18% increase and its profit per share to jump to $0.97 which is a 24% rise. Whereas the revenue forecast remained the same at $7.6 billion, the company forecasted a rise in profits from $3.60-$3.65 per share to $3.65-$3.70 per share as well as a rise in Earnings per share.

With an increase in sales for most of its products, as evident from the increase in sales of the blood cancer drug Revlimid by 19%, another cancer drug Abraxane by 25% and sales of myeloma drug Pomalyst/Imnovid, doubling over the years, Celgene (NASDAQ:CELG) expects further growth almost across the board. One reason Celgene (NASDAQ:CELG) attributes to its improved results is the increased demand for its products with the remainder coming from U.S. price increases.

Besides an expected earnings, the initial reports on Celgene’s (NASDAQ:CELG) study of Crohn’s disease was also a factor for the rise in the stocks of the company. The initial reports of the experiment carried out by Celgene (NASDAQ:CELG) for testing the efficiency of GED-0301 were curious enough to be noticed. Three doses were given to three experimental groups along with another control group. The doses amounted to 10mg, 40mg and 160mg. The first group who were given the 10mg dose demonstrated no significant change but the other groups demonstrated significant effects from the drug.

Thus it was confirmed that a specific amount of the drug GED-0301 could be effective for the patients to relieve them from pain. With the results showing that Celgene’s new drug can be effective, it seems like Celgene (NASDAQ:CELG) has got a potential blockbuster which could further boost its stock value.  An important lesson here is that Celgene (NASDAQ:CELG) unlike many great companies is not trying to rise its earnings through cost-cutting measures or buying excess shares. Instead, it is depending on the growth of its products demands and innovation to surge its earnings.

Moreover, Celgene (NASDAQ:CELG) while using its collaborations could bring forward more blockbuster medicines. Celgene (NASDAQ:CELG) stocks could rise higher still. With the management of Celgene (NASDAQ:CELG) staunch in their belief that through the coming three years Earnings per share of the company would be doubling and the revenues of the company would be growing by at least 20%, it seems that the company could make further leaps for sure.

Even though it’s the best source of revenue, but Revlimid is not the only drug Celgene (NASDAQ:CELG) has in its arsenal. The company has a line-up of a few new drugs that promise to add to its overall revenue; therefore Celgene (NASDAQ:CELG) for the time being should be on every investor’s watch-list.

Celgene (NASDAQ:CELG)’s Abraxane is likely to record sales between $850 and $900 million – a figure that is extremely high. Abraxane’s sales for the second quarter were up by 39% on a year-over-year basis the main reason for which was its approval in Europe’s and US’ pancreatic cancer category.

This year’s first half for Celgene (NASDAQ:CELG) brought sales of $400 million and to reach its low-end milestones the company needs another round of $450 million sales in the year’s second half.

Celgene (NASDAQ: CELG)’s drug for multiple myeloma, Pomalyst got its approval in the year 2013, which is also likely to feature in the company’s third quarter results. Its year-over-year sales went up by 143%; this figure includes only its US sales in the first quarter; the drug was later approved in Europe as well; therefore it is likely to post some healthy sales figures. If all goes well for Pomalyst and it can boost its sales a bit then its sales may hit the $700 million mark by the end of this year.

Celgene (NASDAQ:CELG)’s Otezla was launched this year in April and may not be a strong contributor to the overall revenue of the company yet; it may be the one to watch in the company’s next quarter. Otezla has its FDA psoriatic arthritis and Plaque psoriasis treatment approval. The report may show its sales progress so far; considering the fact that it only had a month in the third quarter, nothing major should be expected from it. However the drug looks promising because unlike its competitors in the market, it can be taken orally whereas others have to be injected.

The drug will take a few years to become a great source of revenue for the company. But it may be difficult for the drug to find its patients among the ones that are already using its competitors; therefore it will have to rely on finding new patients who do not want to rely on injections for treatment. Otezla was one of the market leaders in its second quarter in the category of new psoriatic arthritis’ new patients, which shows its potential.

Celgene (NASDAQ:CELG) is hoping to manufacture treatments for a few other inflammation diseases as well, which include Behcet’s disease, ulcerative colitis and rheumatoid arthritis.

Celgene (NASDAQ:CELG) 52-week high is the best ever for the company and its stock is currently trading closer to this value. The main reason is GED-0301’s sales.

Celgene (NASDAQ:CELG) is classed as elite amongst fellow firms, it has several effective medicinal products and promises more innovative drug existence in its pipeline. This approach has helped them gain a huge market share and catered to their success in the stock market. But the question that arises now is what exactly does Celgene (NASDAQ:CELG) have in its development pipeline. Celgene (NASDAQ:CELG) has over 50 clinical studies, currently. Most of these are experimental drugs, under review by Food and Drug Administration. A total of 18 are in early stage of testing, 17 are at mid-level and 13 are at its final stages. Another 6 drugs have been sent for FDA review and approval.

The drug development pipeline is important as new and innovative experimental drugs should never fall short. For Celgene (NASDAQ:CELG), there hasn’t been a problem, but in the future; it seem Revlimid might need to be replaced. Revlimid, is a drug, used to treat anemia; caused by myelodysplastic syndrome and other types of blood cancer. This drug, up till now, makes 66% of Celgene (NASDAQ:CELG)’s $1.85 billion in net sales. But future forecasts indicate that by 2017, Revlimid will only be able to generate half of the revenue it does now. Hence Celegene has already started looking into the matter for replacements.

According to the new results that emerged through intensive research, there is a possibility that Revlimid might survive in the market well beyond 2019. Currently, it is being tested for other medical conditions, such as:

-          First line and maintenance therapy to diffuse large B cell in lymphoma

-          First stages of follicular lymphoma

-          Relapsed indolen lymphoma treatment

-          For chronic lymphocytic leukemia maintenance therapy

If Revlimid gets approval, it could cater for atleast $1 bilion in annual sales for the company, and result in on-going success of the product. Revlimid is also under study at other geographical locations like Japan and EU, to use for T-cell leukemia and lymphoma and relapsed mantle cell lymphoma. With all these pieces put together, Revlimid might become a giant drug.

Another approach that will be fruitful for the company, in the long run is the anti-inflammatory drug Otezla, used by arthritis patients. Rheumatoid arthritis is quite profitable in terms of sales and is the second largest treatment in the market for arthritis, a very common condition.

At this stage, the combination of its existing drug, and label expansion  of existing drug with development of new products are all working in favor of Celgene (NASDAQ:CELG). The company continues to attract investors to its doorstep.

On the last trade day, the company’ stocks saw a decrease of 2.31 percent in its prices, and the stocks closed at a price of $5.92. The company’s 52 week high is $23 whereas its 52 week low is $2.15, with a total market capitalization of $1.11 billion. In the last trading session, a total of 5.68 million company’s shares exchanged hands. Moreover, sources have it that the company’s total outstanding shares have reached the figures of 186.80 million shares.

News has it Gilead Sciences, Inc. (NASDAQ:GILD) surpassed PepsiCo and went up in the market capitalization category. According to the latest Standard & Poor’s 500 indexes, Gilead Sciences, Inc. (NASDAQ:GILD) took over the number 27 spot that was previously held by PepsiCo, by getting a +1.78%.

Talking about the stocks of Gilead Sciences, Inc. (NASDAQ:GILD), in the trading session, company’s stocks opened at a price of $87.25 and closed at an increased price of $88.68, after hitting the highest price figures of $88.96. The weekly performance shown by company’s stocks was recorded to be 3.97%. The company has a 52 week high of $88.96 and a 52 week low of $54.19, with a market capitalization of $136.58 billion.

On Wednesday, Celgene Corporation (NASDAQ:CELG) disclosed to the public that the company was recently running its tests on a drug, which could be used to treat arthritis; however, the tests remained unsuccessful. Interestingly, this admission of the company’s failure seems to have no effect on the share prices of the company.

In last trading session, company’s stocks started at a price of $84.39 and ended at an increased price of $87.52, with the highest price hitting the figures of $87.91. Moreover, 7.60 million shares of Celgene Corporation (NASDAQ:CELG) exchanged hands, whereas the company’s average trading volume was 5.03 million shares. As far as company’s 52 week high and low figures are concerned, the numbers are reported to be around $7.97 and $4.05 respectively.

According to the Securities and Exchange Commission filing, the Chief Executive Officer of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Jack Lief, recently sold around 40 percent of the company’s stocks. Jack Lief sold a total of 223,525 shares at a mean price of $5.85, which brought the total price to approximately $1.3 million.

On the last trade day, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed its stocks at a price of $4.95. As far as company’s stocks’ institutional and insider ownership figures are concerned, the numbers are reported to be 47.10% and 0.70% respectively. According to the latest reports, the company’s outstanding shares have come to a grand total of 219.66 million shares, whereas 214.40 million shares among them have been floated.

The disease Psoriasis is a chronic inflammatory skin disorder, and the cause of this condition is unknown. Recently, Celgene Corporation (NASDAQ:CELG) has presented data to FDA, from the studies in last week, and get approval of the therapy for psoriatic arthritis. Celgene Corporation (NASDAQ:CELG) is now waiting for authorization by FDA for the wider psoriasis population, and reportedly the decision is expected in September.

If the health company receives the latter approval of it, the analysts reckon Otezla could generate peak annual sales of $1.2 Billion.

On last trading day Celgene Corporation (NASDAQ:CELG) ended up -3.74% lower to close at $144.40 while trading in the range of $143.10 – $151.49. Its return on assets (ROA) is 11.50% while return on investment (ROI) is 15.40%. Celgene Corporation (NASDAQ:CELG)monthly performance is -11.73%. CELG belongs to Healthcare sector with market capitalization of 58.63B and has 0.20% insider ownership. It is -17.33% away from its 52 week high. This Year Company’s Earnings per Share (EPS) growth is 2.10% and next year’s estimated EPS growth is 31.52%. Analysts mean target price for Celgene Corporation (NASDAQ:CELG) is $189.72.